Your browser doesn't support javascript.
loading
Major clinical research advances in gynecologic cancer in 2016: 10-year special edition / 부인종양
Journal of Gynecologic Oncology ; : e45-2017.
Article in English | WPRIM | ID: wpr-163714
ABSTRACT
In 2016, 13 topics were selected as major research advances in gynecologic oncology. For ovarian cancer, study results supporting previous ones regarding surgical preventive strategies were reported. There were several targeted agents that showed comparable responses in phase III trials, including niraparib, cediranib, and nintedanib. On the contrary to our expectations, dose-dense weekly chemotherapy regimen failed to prove superior survival outcomes compared with conventional triweekly regimen. Single-agent non-platinum treatment to prolong platinum-free-interval in patients with recurrent, partially platinum-sensitive ovarian cancer did not improve and even worsened overall survival (OS). For cervical cancer, we reviewed robust evidences of larger-scaled population-based study and cost-effectiveness of nonavalent vaccine for expanding human papillomavirus (HPV) vaccine coverage. Standard of care treatment of locally advanced cervical cancer (LACC) was briefly reviewed. For uterine corpus cancer, new findings about appropriate surgical wait time from diagnosis to surgery were reported. Advantages of minimally invasive surgery over conventional laparotomy were reconfirmed. There were 5 new gene regions that increase the risk of developing endometrial cancer. Regarding radiation therapy, Post-Operative Radiation Therapy in Endometrial Cancer (PORTEC)-3 quality of life (QOL) data were released and higher local control rate of image-guided adaptive brachytherapy was reported in LACC. In addition, 4 general oncology topics followed chemotherapy at the end-of-life, immunotherapy with reengineering T-cells, actualization of precision medicine, and artificial intelligence (AI) to make personalized cancer therapy real. For breast cancer, adaptively randomized trials, extending aromatase inhibitor therapy, and ribociclib and palbociclib were introduced.
Subject(s)

Full text: Available Index: WPRIM (Western Pacific) Main subject: Ovarian Neoplasms / Quality of Life / Brachytherapy / Breast Neoplasms / Artificial Intelligence / Aromatase / T-Lymphocytes / Uterine Cervical Neoplasms / Endometrial Neoplasms / Minimally Invasive Surgical Procedures Type of study: Controlled clinical trial / Diagnostic study / Prognostic study Limits: Female / Humans Language: English Journal: Journal of Gynecologic Oncology Year: 2017 Type: Article

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: WPRIM (Western Pacific) Main subject: Ovarian Neoplasms / Quality of Life / Brachytherapy / Breast Neoplasms / Artificial Intelligence / Aromatase / T-Lymphocytes / Uterine Cervical Neoplasms / Endometrial Neoplasms / Minimally Invasive Surgical Procedures Type of study: Controlled clinical trial / Diagnostic study / Prognostic study Limits: Female / Humans Language: English Journal: Journal of Gynecologic Oncology Year: 2017 Type: Article